Cadonilimab  (Synonyms: AK104)

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC)^[1][2][3][4].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Chimeric; Humanized

PD1^[1]

Cadonilimab (0-100 nM, 10-120 min) maintains a high affinity for Jurkat-CTLA4 and Jurkat-PD1 cells in vitro after iodine modification^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cadonilimab (3.7 MBq, tail i.v., a single dose) modified with ¹²⁴I largely enriches in the spleen, tumor sites and results in enrichment of PD1/CTLA4 positive immune cells at the tumor sites in humanized mice with MC38-hPD-L1 cell xenografts^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2394841-59-7

Liquid

Colorless to light yellow

[Cadonilimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa-[scFv-heavy-lambda]2

• 
  Immobilized Cadonilimab can bind Human PD-1 Protein (ECD, His Tag). The EC₅₀ for this effect is 0.197 ng/mL.
• 
  Immobilized Cadonilimab can bind Human CTLA-4 Protein (His Tag). The EC₅₀ for this effect is 3.07 ng/mL.

• [1]. Antonarelli G, et al. Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals (Basel). 2021 Aug 31;14(9):884.  [Content Brief]

  [2]. Kaplon H, et al. Antibodies to watch in 2022. MAbs. 2022 Jan-Dec;14(1):2014296.  [Content Brief]

  [3]. Chen PY, et al. Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab. Front Immunol. 2023 Aug 3;14:1188523.  [Content Brief]

  [4]. Hou X, et al. Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice. Biomed Pharmacother. 2024 Jun;175:116669.  [Content Brief]